LLR ICB Position Statement Subcutaneous Injection of Low Molecular Weight Heparin in Primary Care.(121 KB)
Date added: 9th Nov 2025
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| PHENOBARBITAL | Yellow | Epilepsy |
MHRA alert (Dec 2014) adverse effects on bone and MHRA alert (Nov 2017) updated advice on switching between different manufacturers’ products |
| 1mg Estradiol and 100mg Micronised progesterone (Bijuve) | Green | Continuous combined hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women | |
| ABALOPARATIDE (NEW) | Red | Treating osteoporosis after menopause | |
| AVATROMBOPAG (Doptelet®) (UPDATED) | Red | Thrombocytopenia in people with chronic liver disease | |
| DOXYLAMINE SUCCINATE AND PYRIDOXINE (Xonvea®) (UPDATED) | Do not prescribe | Hyperemesis in pregnancy | |
| ENOXAPARIN | Green | Thromboprophylaxis and treatment of DVT and PE |
Prescribe by brand name INHIXA® as different brands have different injection techniques. Courses started during the dalteparin shortage can be continued to be supplied in primary care LLR ICB Position Statement Subcutaneous injection of Low Molecular Weight Heparin in Primary Care |
| ENOXAPARIN | Green | Low INR used in line with primary care warfarin guidance |
Prescribe by brand name INHIXA® as different brands have different injection techniques. Warfarin Guidelines for Primary Care LLR ICB Position Statement Subcutaneous injection of Low Molecular Weight Heparin in Primary Care |
| ENOXAPARIN (Inhixa®) | Yellow | Antenatal Indications |
LLR ICB Position Statement Subcutaneous injection of Low Molecular Weight Heparin in Primary Care |
| FLUPHENAZINE DECANOATE (UPDATED) | Do not prescribe | Schizophrenia and other psychoses |
See the LLR Antipsychotic Prescribing Guide Non- Formulary No new initiations, licensed prep no longer available. Patients established on therapy may continue. |
| GARADACIMAB (Andembry®) (NEW) | Red | Preventing recurrent attacks of hereditary angioedema in people 12 years and over |
Funding From 8th January 2026 |
| GUSELKUMAB (Tremfya®) (UPDATED) | Red | For treating moderately to severely active ulcerative colitis |
in line with NICE TA1094 |
| GUSELKUMAB (Tremfya®) (NEW) | Red | For previously treated moderately to severely active Crohn's disease |
in line with NICE TA1095 |
| LIXISENATIDE (Lyxumia®) (UPDATED) | Do not prescribe | Type 2 diabetes |
Product discontinued 2023. Non-Formulary |
| MEMANTINE (UPDATED) | Green | Alzheimer's Disease |
GPs may initiate memantine in patients already established on treatment in memory services and stabilised on a cholinesterase inhibitor. The aim is to reduce pressure on memory clinics, freeing up capacity to assess new This change is permissive, not mandatory. No clinician is expected to prescribe outside In line with the NICE NG 97 & The Dementia Prescribing Guide |
| MEPACRINE (NEW) | Red | Treatment of skin inflammation associated with Lupus such as Discoid lupus erythematosus and Subacute cutaneous lupus erythematosus. | |
| NALTREXONE (UPDATED) | Red | For use in opioid dependency |
To be initiated by specialists for maintenance treatment to help prevent relapse in opioid dependence. |
| PROMAZINE (UPDATED) | Do not prescribe | Short term adjunctive management of psychomotor agitation |
Non-Formulary No longer recommended for use in dementia |
| Relugolix (Orgovyx®) (UPDATED) | Do not prescribe | For treating hormone sensitive prostate cancer |
Relugolix has been temporarily removed from the LLR formulary, pending development of local clinical pathway and funding model to support safe, equitable and sustainable implementation across LLR health system. Please see LLR APC Position Statement: Relugolix (Orgovyx®) for Hormone-Sensitive Prostate Cancer |
| SEBETRALSTAT (Ekterly®) (NEW) | Red | Acute attacks of hereditary angioedema (HAE) for FOC Scheme |
Approved in accordance with MHRA Early Access to Medicines Scheme for the treatment of hereditary angioedema attacks in adult and adolescent patients aged 12 years and older. |
| TRIAMCINOLONE (Intracinol®) (NEW) | Red | Visualisation of vitreous / epithelial membranes |
Other Updates on this Website
Recent documents from LLR APC and TAS
LLR Adult Asthma Guideline (≥18 years) AIR and MART FAQ(490 KB)
Date added: 6th Nov 2025
LLR APC Meeting Minutes October 2025(314 KB) - LMSG/LLR APC minutes
Date added: 6th Nov 2025
LLR APC Position Statement: Relugolix (Orgovyx®) for Hormone-Sensitive Prostate Cancer(170 KB)
Date added: 5th Nov 2025
Neuroleptic Malignant Syndrome Guidelines(253 KB) - Guidelines
Date added: 10th Oct 2022
Edoxaban Patient Information Leaflet(210 KB) - Guidelines
Date added: 2nd Jul 2018
Rivaroxaban Patient Information Leaflet(219 KB) - Guidelines
Date added: 2nd Jul 2018
Dabigatran Patient Information Leaflet(212 KB) - Guidelines
Date added: 2nd Jul 2018
Apixaban Patient Information Leaflet(211 KB) - Guidelines
Date added: 2nd Jul 2018
LLR APC Members(78 KB) - Uncategorised
Date added: 28th May 2015
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more